Breast cancer is the most frequently diagnosed cancer and the principal cause of mortality
by malignancy in women and represents a main problem for public health worldwide. Tumor …

Tumor necrosis factor (TNF) is widely accepted as a tumor-suppressive cytokine via its
ubiquitous receptor TNF receptor 1 (TNFR1). The other receptor, TNFR2, is not only …

Major barriers to cancer therapy include the lack of selective inhibitors of regulatory T cells
(Tregs) and the lack of broadly applicable ways to directly target tumors through frequently …

Tumour acidosis contributes to cancer progression by inhibiting anti-tumour immunity.
However, the effect of acidosis on anti-tumour T cell phenotypes in oesophageal …

Simple Summary Tumor necrosis factor (TNF) and its closely related cytokine, lymphotoxin
alpha (LTα), are part of the TNF superfamily and exert their functions via both overlapping …

Tumor necrosis factor-alpha (TNFα) can bind two distinct receptors (TNFR1/2). The
transmembrane form (tmTNFα) preferentially binds to TNFR2. Upon tmTNFα cleavage by the …

In the past decade, nanomedicine research has provided us with highly useful agents
(nanoparticles) delivering therapeutic drugs to target cancer cells. The present review …

Objective: Tumor necrosis factor (TNF) receptor type II (TNFR2) is expressed by a wide
spectrum of tumor cells including colon cancer, non-Hodgkin lymphoma, myeloma, renal …

The appreciation that cancer growth is promoted by a dynamic tumor microenvironment
(TME) has spawned novel approaches to cancer treatment. New therapies include agents …

Cationic anticancer peptides have exhibited potent anti-proliferative and anti-inflammatory
effects in neoplastic illness conditions. LyeTx Ib is a synthetic peptide derived from Lycosa …